Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.55 +4.1%	$5.86	$4.65 ▼ $10.24	$92.82M	0.49	72,334 shs	55,480 shs
GNLX Genelux	$2.45 +1.2%	$2.58	$1.60 ▼ $5.89	$92.45M	-0.33	190,350 shs	83,983 shs
MTCR Metacrine	$0.58	$0.57	$0.30 ▼ $0.59	$24.75M	-0.73	225,834 shs	83,889 shs
OPTN OptiNose	$9.60	$9.32	$4.82 ▼ $20.03	$97.22M	-0.88	63,485 shs	N/A

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	+2.59%	-5.93%	-12.87%	-18.26%	-27.17%
GNLX Genelux	-0.81%	-5.04%	-6.84%	-32.69%	-9.59%
MTCR Metacrine	0.00%	0.00%	0.00%	0.00%	0.00%
OPTN OptiNose	0.00%	0.00%	+2.13%	+70.82%	-40.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	1.8467 of 5 stars	3.5	3.0	0.0	0.0	2.0	0.8	0.0
GNLX Genelux	1.2654 of 5 stars	3.6	0.0	0.0	0.0	3.0	0.0	0.0
MTCR Metacrine	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.281 of 5 stars	1.0	5.0	0.0	4.2	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$17.00	206.31% Upside
GNLX Genelux	3.20	Buy	$17.75	624.49% Upside
MTCR Metacrine	0.00	N/A	N/A	N/A
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside

Current Analyst Ratings Breakdown

Latest MTCR, OPTN, GNLX, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/8/2025	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$25.00 ➝ $23.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/31/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/25/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/21/2025	OPTN OptiNose	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$15.00 ➝ $9.00
3/21/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$18.00 ➝ $9.00
3/20/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.69M	25.19	N/A	N/A	$2.47 per share	2.25
GNLX Genelux	$8K	11,556.34	N/A	N/A	$0.73 per share	3.36
MTCR Metacrine	N/A	N/A	N/A	N/A	$1.36 per share	N/A
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$1.07	N/A	N/A	N/A	N/A	-31.63%	-27.76%	8/11/2025 (Estimated)
GNLX Genelux	-$28.30M	-$0.88	N/A	N/A	N/A	N/A	-105.05%	-80.16%	8/13/2025 (Estimated)
MTCR Metacrine	-$62.21M	-$1.03	N/A	∞	N/A	N/A	-84.88%	-59.33%	N/A
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)

Latest MTCR, OPTN, GNLX, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
3/28/2025	Q4 2024	GNLX Genelux	-$0.17	-$0.26	-$0.09	-$0.26	N/A	N/A
3/26/2025	Q4 2024	OPTN OptiNose	-$0.70	-$0.03	+$0.67	-$0.03	$21.02 million	$21.47 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
MTCR Metacrine	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
GNLX Genelux	N/A	6.47	6.47
MTCR Metacrine	0.34	12.15	12.15
OPTN OptiNose	N/A	0.79	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
GNLX Genelux	37.33%
MTCR Metacrine	37.72%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
GNLX Genelux	9.30%
MTCR Metacrine	13.80%
OPTN OptiNose	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
GNLX Genelux	10	37.74 million	31.33 million	Not Optionable
MTCR Metacrine	10	42.57 million	36.70 million	Not Optionable
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable

MTCR, OPTN, GNLX, and COYA Headlines

Recent News About These Companies

HC Wainwright Estimates OptiNose's Q2 Earnings (NASDAQ:OPTN)

May 23, 2025 | marketbeat.com

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by D. E. Shaw & Co. Inc.

May 23, 2025 | marketbeat.com

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21, 2025 | finance.yahoo.com

HC Wainwright Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)

May 21, 2025 | marketbeat.com

OptiNose, Inc. (NASDAQ:OPTN) is Stonepine Capital Management LLC's 8th Largest Position

May 20, 2025 | marketbeat.com

Optinose Stockholders Approve Merger with Paratek

May 16, 2025 | tipranks.com

Bridgeway Capital Management LLC Sells 227,387 Shares of OptiNose, Inc. (NASDAQ:OPTN)

May 16, 2025 | marketbeat.com

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Renaissance Technologies LLC

May 10, 2025 | marketbeat.com

OptiNose (OPTN) to Release Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

Bleichroeder LP Trims Position in OptiNose, Inc. (NASDAQ:OPTN)

May 7, 2025 | marketbeat.com

Geode Capital Management LLC Has $576,000 Stake in OptiNose, Inc. (NASDAQ:OPTN)

May 5, 2025 | marketbeat.com

Acorn Capital Advisors LLC Makes New $2.82 Million Investment in OptiNose, Inc. (NASDAQ:OPTN)

May 4, 2025 | marketbeat.com

OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by MVM Partners LLC

May 3, 2025 | marketbeat.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

April 29, 2025 | businesswire.com

Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income

March 28, 2025 | msn.com

Optinose reports Q4 EPS (3c) vs ($1.33) last year

March 27, 2025 | markets.businessinsider.com

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

March 26, 2025 | markets.businessinsider.com

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

March 26, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

March 25, 2025 | morningstar.com

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

March 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTCR, OPTN, GNLX, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.55 +0.22 (+4.13%)

Closing price 06/2/2025 03:59 PM Eastern

Extended Trading

$5.58 +0.03 (+0.45%)

As of 04:09 AM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Genelux NASDAQ:GNLX

$2.45 +0.03 (+1.24%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$2.49 +0.04 (+1.63%)

As of 06/2/2025 07:31 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Metacrine NASDAQ:MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)

As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time